{
    "id": 25507,
    "fullName": "AKT1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "AKT1 over exp indicates an over expression of the Akt1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 207,
        "geneSymbol": "AKT1",
        "terms": [
            "AKT1",
            "AKT",
            "CWS6",
            "PKB",
            "PKB-ALPHA",
            "PRKBA",
            "RAC",
            "RAC-ALPHA"
        ]
    },
    "variant": "over exp",
    "createDate": "10/17/2016",
    "updateDate": "08/22/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8881,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26496,
                "profileName": "AKT1 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8896,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA E545K resulted in resistance to Pictilisib (GDC-0941) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26498,
                "profileName": "AKT1 over exp PIK3CA E545K"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12139,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12D and demonstrating high AKT expression and activity was insensitive to growth inhibition by single agent MEK inhibitors, including Selumetinib (AZD6244), in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 28492,
                "profileName": "AKT1 over exp AKT2 over exp AKT3 over exp KRAS G12D"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12142,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12D and demonstrating high AKT expression and activity was insensitive to growth inhibition by single agent MEK inhibitors, including Mekinist (trametinib), in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 28492,
                "profileName": "AKT1 over exp AKT2 over exp AKT3 over exp KRAS G12D"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12141,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12D and demonstrating high AKT expression and activity was insensitive to growth inhibition by single agent MEK inhibitors, including PD-0325901, in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 28492,
                "profileName": "AKT1 over exp AKT2 over exp AKT3 over exp KRAS G12D"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12140,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12D and demonstrating high AKT expression and activity was insensitive to growth inhibition by single agent MEK inhibitors, including Refametinib (BAY86-9766), in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 28492,
                "profileName": "AKT1 over exp AKT2 over exp AKT3 over exp KRAS G12D"
            },
            "therapy": {
                "id": 888,
                "therapyName": "Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12144,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and Triciribine (API-2) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line harboring KRAS G12D and demonstrating high AKT expression and activity in culture, however, the concentration of Mekinist (trametinib) was above the clinically relevant limit (PMID: 28957417).",
            "molecularProfile": {
                "id": 28492,
                "profileName": "AKT1 over exp AKT2 over exp AKT3 over exp KRAS G12D"
            },
            "therapy": {
                "id": 6312,
                "therapyName": "Trametinib + Triciribine",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26495,
            "profileName": "AKT1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26496,
            "profileName": "AKT1 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26498,
            "profileName": "AKT1 over exp PIK3CA E545K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28492,
            "profileName": "AKT1 over exp AKT2 over exp AKT3 over exp KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}